CriticalAntiretroviral, HIV protease inhibitor×Class Ia antiarrhythmic (sodium channel blocker with intermediate kinetics)
Updated · Methodology
Mechanism
The liver eliminates most quinidine through CYP3A4 (quinidine label, US Food and Drug Administration, FDA), and atazanavir inhibits this enzyme, so quinidine levels can rise (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA). Quinidine has a narrow therapeutic margin, and the atazanavir SmPC contraindicates it precisely because of the potential CYP3A inhibition (EMA). Ritonavir inhibits this enzyme more strongly than atazanavir itself, and cobicistat is also a potent CYP3A inhibitor (atazanavir and atazanavir/cobicistat SmPCs, EMA). Quinidine prolongs the QT interval in a dose-related way, and this may lead to polymorphic ventricular tachycardia, including torsade de pointes (FDA quinidine label). The documents give no figures for this pair.
Symptoms
The danger of this combination is serious or life-threatening reactions such as cardiac arrhythmias (atazanavir label, US Food and Drug Administration, FDA). QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. Besides torsade de pointes, quinidine can cause frequent extrasystoles, ventricular tachycardia, ventricular flutter and ventricular fibrillation. The risk of torsade de pointes rises with a slow heart rate, low potassium, magnesium or calcium and high quinidine levels, although it can also occur without these factors (FDA quinidine label). In some people atazanavir prolongs the PR interval: atrioventricular conduction changes are usually asymptomatic and generally limited to first-degree block, but second-degree block has also been reported (atazanavir FDA label).
Management
The combination is contraindicated. The European atazanavir summary of product characteristics (SmPC) lists quinidine among its contraindications whether or not a booster is used (atazanavir SmPC, European Medicines Agency, EMA), and the atazanavir/cobicistat SmPC also contraindicates it (EMA). The US atazanavir label contraindicates quinidine in regimens with ritonavir. Without ritonavir, the combination has not been studied, and for that regimen the label advises caution and monitoring of quinidine concentrations (atazanavir label, US Food and Drug Administration, FDA). The European SmPC is stricter. With ritonavir, the ritonavir SmPC also contraindicates quinidine (ritonavir SmPC, EMA). Quinidine is not in the Spanish medicines register CIMA, which lists only hydroquinidine, a different substance. If the drugs have nevertheless been taken together and haemodynamically unstable polymorphic ventricular tachycardia, including torsade de pointes, develops, stop quinidine and perform immediate cardioversion or overdrive pacing. Look for low potassium, magnesium and calcium and, if possible, correct them promptly (FDA quinidine label, overdosage section).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Reyataz (atazanavir) prescribing information (2024)– DailyMed setid 165cff62-b284-4a27-a65d-9ec8a5bfcdd8, revisión 12/2024, secciones 4 y 7.3
- EMA: Ficha técnica: Ritonavir (EU/1/96/016), sección 4.3 (2026)– EMA, Norvir, ficha técnica en CIMA (nº registro 96016005), consultada 03.10.2026, secciones 4.3, 4.4 y 4.5
- FDA: Quinidine Sulfate Tablets USP (quinidine sulfate) prescribing information (2023)– FDA, DailyMed setid b0d6341b-d880-4f0b-8844-bc788c03004a (Epic Pharma), revisión 11/2023, secciones Clinical Pharmacology, Warnings, Precautions (Drug Interactions) y Overdosage
- EMA: Ficha técnica: Atazanavir, Reyataz (EU/1/03/267), sección 4.3 (2026)– EMA, Reyataz 300 mg cápsulas (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 03267008, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir/cobicistat, Evotaz (EU/1/15/1025), sección 4.3 (2026)– EMA, Evotaz 300 mg/150 mg comprimidos (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5